Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tim Loewenstein

Physician Assistant, Medical Meridian, ID Physician Assistant

NPI 1376597377 CMS profile 10575249

3280 E Lanark Dr, Meridian, ID 83642

Open in the dashboard

General payments

$1,784

98 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tim Loewenstein of Meridian, ID is reported in the CMS Open Payments database as having received $1,784 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $400 23
2024 General $678 36
2023 General $520 28
2022 General $187 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tim Loewenstein
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Tim Loewenstein were reported at $400. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Tim Loewenstein Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $187 $185 $55–$649 $149
2023 $520 $199 $58–$717 $160
2024 $678 $206 $62–$740 $164
2025 $400 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $346 16 payments
  2. Pfizer Inc. $233 13 payments
  3. Novo Nordisk Inc $182 11 payments
  4. Amgen Inc. $132 8 payments
  5. Ironshore Pharmaceuticals Inc. $100 4 payments
  6. AstraZeneca Pharmaceuticals LP $93 6 payments
  7. GlaxoSmithKline, LLC. $90 6 payments
  8. Merck Sharp & Dohme Corporation $62 4 payments
  9. Lilly USA, LLC $62 4 payments
  10. Sanofi Pasteur Inc. $62 3 payments
  11. Other $422 23 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,784 98 payments
Products named General payments · program years 2022–2025
  1. UBRELVY $311 14 payments
  2. QULIPTA $245 11 payments
  3. PREVNAR 20 $166 9 payments
  4. COMIRNATY $157 9 payments
  5. RYBELSUS $132 8 payments
  6. Ozempic $132 8 payments
  7. JORNAY PM $100 4 payments
  8. EVENITY $97 6 payments
  9. ABRYSVO $89 5 payments
  10. Prolia $83 5 payments
  11. Other $1,341 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

3,272

Median for Physician Assistant: 241

Drug cost

$235,319

Median for Physician Assistant: $4,110

Branded share of claims

16.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $45,174
Farxiga Dapagliflozin Propanediol Brand 23 $33,035
Ozempic Semaglutide Brand 27 $30,031
Xarelto Rivaroxaban Brand 16 $23,270
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $20,785
Trulicity Dulaglutide Brand 18 $20,689
Mounjaro Tirzepatide Brand 14 $14,489
Arnuity Ellipta Fluticasone Furoate Brand 13 $6,746
Atorvastatin Calcium Generic 262 $3,384
Levothyroxine Sodium Generic 260 $2,387

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$32,361

Of which drugs: $14,221

Medicare patients

101

Average age 71

Services billed

867

53 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 38%
Diabetes 29%
Depression 22%
Chronic kidney disease 18%
Cancer 15%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 12 12 $1,707
Vaccine for influenza for injection into muscle 90653 Office 13 13 $929

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $64
$64 — —
QULIPTA
  • AbbVie, Inc. $64
$64 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $46
$46 — —
Azstarys
  • Corium, Inc. $39
$39 — —
Wegovy
  • Novo Nordisk Inc $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record